Skip to main content
Close
Home
Society of Hospital Medicine
Presented by Society of Hospital Medicine
Home
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

M. Alexander Otto

M. Alexander Otto began his reporting career early in 1999 covering the pharmaceutical industry for a national pharmacists' magazine and freelancing for the Washington Post and other newspapers. He then joined BNA, now part of Bloomberg News, covering health law and the protection of people and animals in medical research. Alex next worked for the McClatchy Company. Based on his work, Alex won a year-long Knight Science Journalism Fellowship to MIT in 2008-2009. He joined the company shortly thereafter. Alex has a newspaper journalism degree from Syracuse (N.Y.) University and a master's degree in medical science -- a physician assistant degree -- from George Washington University. Alex is based in Seattle.

News

Adding venetoclax improves ibrutinib outcomes in CLL

Author:
M. Alexander Otto
Publish date: January 23, 2023

A small study yields sanguine news about a combination treatment, as hematologists await phase 3 results.

  • Read More

News

FDA approves first gene therapy for bladder cancer

Author:
M. Alexander Otto
Publish date: December 16, 2022

The U.S. Food and Drug Administration

  • ...

  • Read More

News

Beta-thalassemia: Benefits of gene therapy outweigh costs

Author:
M. Alexander Otto
Publish date: December 14, 2022

Following treatment with betibeglogene autotemcel, some patients went without transfusions for 8 years and counting.

  • Read More

News

Poorly matched stem cell transplants linked to ancestry

Author:
M. Alexander Otto
Publish date: December 10, 2022

To address disparities, medical institutions also need to improve their assessments of financial hardship.

  • Read More

News

FDA approves first gene therapy for hemophilia B

Author:
M. Alexander Otto
Publish date: November 22, 2022

The gene therapy will cost $3.5 million, making it the most expensive treatment to date.

  • Read More

News

FDA grants accelerated approval for new treatment of female cancers

Author:
M. Alexander Otto
Publish date: November 17, 2022

Eligible patients for mirvetuximab soravtansine include those with folate receptor alpha, chemo resistant ovarian, fallopian and peritoneal...

  • Read More

News

Experts opine on hemophilia treatments

Author:
M. Alexander Otto
Publish date: June 21, 2022

For hemophilia A prophylaxis, debate continues over factor versus non-factor replacement therapy, optimal trough levels, and more.

  • Read More

News

Adding immunotherapy to chemo in lung cancer improves patient outcomes, new data show

Author:
M. Alexander Otto
Publish date: April 5, 2022

Patient-reported outcomes are often released well after efficacy data, making treatment decisions more challenging.

  • Read More

News

Symptoms, not pelvic exams, pick up most endometrial cancer recurrences

Author:
M. Alexander Otto
Publish date: March 23, 2022

The findings speak to the anxiety of shifting to telemedicine during COVID-19.

  • Read More

News

Complex surgery 10 times more likely with some ovarian tumors

Author:
M. Alexander Otto
Publish date: March 23, 2022

Imaging, tumor subtype predict debulking success in advanced ovarian cancer.

  • Read More

News

Intensity-modulated radiotherapy reduces esophagitis in palliative NSCLC

Author:
M. Alexander Otto
Publish date: March 16, 2022

What’s the balance between tumor coverage and sparing healthy tissue in the palliative setting?

  • Read More

News

FDA approves neoadjuvant nivolumab/chemo for early-stage NSCLC

Author:
M. Alexander Otto
Publish date: March 8, 2022

Nivolumab is the first immune checkpoint inhibitor to be approved for resectable NSCLC.

  • Read More

News

Bladder cancer need not always require radical cystectomy

Author:
M. Alexander Otto
Publish date: March 3, 2022

The oncologic outcomes are equivalent whether patients have trimodal therapy or radical cystectomy.

  • Read More

News

63% of patients with upper tract urothelial carcinoma respond to chemo before surgery

Author:
M. Alexander Otto
Publish date: February 24, 2022

Study authors suggest neoadjuvant chemotherapy should be a new standard of care for high-grade upper tract urothelial carcinoma.

  • Read More

News

MRI far safer than CT for guiding radiotherapy in prostate cancer

Author:
M. Alexander Otto
Publish date: February 24, 2022

MRI guidance more than halved the risk of genitourinary toxicities.

  • Read More

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »
An Official Publication of the Society of Hospital Medicine

Society of Hospital Medicine
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Copyright  © 2023 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Menu Close